1. Home
  2. SYBX

SYBX

Synlogic Inc.

Logo Synlogic Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Founded: N/A Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 20.6M IPO Year: N/A
Target Price: $15.50 AVG Volume (30 days): 136.2K
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -8.81 EPS Growth: N/A
52 Week Low/High: $0.23 - $5.71 Next Earning Date: 05-19-2024
Revenue: $3,371,000 Revenue Growth: 185.68%
Revenue Growth (this year): -92% Revenue Growth (next year): 1594.26%

Share on Social Networks: